In particular, the markedly reduced proliferative properties, the affection of the cell morphology and the reduced cellular viability of PLEKHG5-deficient cells indicate that interference with this complex molecular network might turn out to be a promising therapeutic strategy for other glioma cell lines and further in primary GBM. The gene discussed is PLEKHG5; the disease is glioblastoma.